GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.76 USD | +0.09% |
|
+1.99% | -20.15% |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 36 M€ | +2.29% | - | |
| 0.35% | 322 M€ | +13.88% | - | |
| 0.35% | 29 M€ | -.--% | - | |
| 0.34% | 1,848 M€ | +18.39% | - | |
| 0.34% | 559 M€ | +14.30% | - | |
| 0.34% | 6 M€ | +17.98% | - | |
| 0.33% | 133 M€ | +9.18% | - | |
| 0.32% | 18 M€ | +3.41% | - | |
| 0.32% | 26 M€ | +24.50% | - | |
| 0.29% | 825 M€ | +11.11% | ||
| 0.29% | 9 M€ | +7.98% | - | |
| 0.28% | 38 M€ | -.--% | ||
| 0.27% | 1 M€ | -.--% | ||
| 0.26% | 7 M€ | +0.11% | - | |
| 0.25% | 55 M€ | +11.89% | ||
| 0.25% | 261 M€ | -.--% | - | |
| 0.25% | 200 M€ | +11.72% | - | |
| 0.25% | 35 M€ | +14.31% | - | |
| 0.25% | 488 M€ | +14.78% | ||
| 0.25% | 205 M€ | -.--% | ||
| 0.24% | 20 M€ | +0.79% | - | |
| 0.23% | 61 M€ | +24.01% | - | |
| 0.21% | 35 M€ | +10.58% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.7
USD
Average target price
82.7
USD
Spread / Average Target
+27.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.15% | 80.61B | |
| +47.68% | 765B | |
| -6.37% | 354B | |
| +20.25% | 331B | |
| +9.41% | 299B | |
| +18.87% | 248B | |
| -1.96% | 219B | |
| +11.11% | 216B | |
| +5.33% | 164B | |
| -2.31% | 162B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.
